Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Neuroblastoma and NBAS-Deficiency Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for NBAS drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | NBAS Recombinant Protein (WD40 Domain / Truncated) High purity (>95%), Endotoxin Controlled (<1 EU/µg). Sequence Verified. HEK293 expressed. |
View NBAS Products |
| Gene Delivery | NBAS Promise-ORF / Lentivirus Full-length ORF for stable cell line construction and rescue assays. |
View NBAS Products |
| Benchmark Ab | Anti-NBAS Recombinant Antibody Recombinant positive control for Western Blot and IHC. |
View NBAS Products |
| Validator | NBAS siRNA Set For knockdown verification in functional assays. |
View NBAS Products |
| Related Target A | STX18 (Syntaxin 18) Key partner in the Golgi-to-ER retrograde transport NRZ complex. |
View STX18 Products |
| Related Target B | USE1 (Unconventional SNARE in the ER 1) Essential component of the syntaxin 18-containing SNARE complex. |
View USE1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Reconstitution of Large Multi-Protein NRZ Complex | Sequence Verified, High Purity (>95%) recombinant NBAS and partner proteins (STX18, USE1) for robust in vitro binding assays. |
| Expression of High Molecular Weight Protein (~274 kDa) | HEK293 Expressed (Native Glycosylation) and domain-specific constructs (e.g., WD40 domain) to optimize solubility and yield. |
| Lack of Validated Controls for Knockdown/Rescue | Sequence-verified siRNA sets and transfection-ready Lentiviruses with endotoxin-controlled plasmid preps. |
| Non-Specific Interaction in Screening | High-purity, mass spectrometry-verified protein batches to minimize false positives in PPI screening. |
Live NBAS R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for NBAS therapeutics is diversifying, with major players shifting focus from traditional oncology targets to targeted RNA therapeutics and gene therapies. As first-generation therapies for neuroblastoma reach clinical maturity, the next wave of R&D is targeting the NRZ (Nag-Rint1-Zw10) transport complex and gene replacement strategies for NBAS-deficient rare diseases (such as SOPH syndrome and infantile acute liver failure).
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule / PPI Inhibitors | Academic Institutes, Biotech Startups | Neuroblastoma, Breast Cancer | Protein-Protein Interaction (PPI) Assay (Need high-purity recombinant NBAS & STX18) |
| RNAi / Oligonucleotide | Alnylam, RNA Therapeutics Biotechs | NBAS-amplified Malignancies | Knockdown Validation (Need sequence-verified siRNA & Lentivirus) |
| Gene Therapy (Lenti/AAV) | Rare Disease Consortia, Gene Therapy Biotechs | SOPH Syndrome, Infantile Acute Liver Failure | Functional Rescue Assay (Need high-titer Lentivirus / Promise-ORF) |